# Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

> **NCT06910124** · PHASE2 · RECRUITING · sponsor: **Dickran Kazandjian, MD** · enrollment: 32 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Linvoseltamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06910124
- **Lead sponsor:** Dickran Kazandjian, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2032-12-02
- **Final completion:** 2032-12-02
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910124, "Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06910124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*